Inhibition of undesired effect of platinum compounds

Details Inhibition of undesired effect of platinum compounds Inhibition of undesired effect of platinum compounds

1984-01-05

1986-04-08

Robinson, Allen J.

Drug, bio-affecting and body treating compositions

Identification or warning feature

Taste or smell or chemical irritation to the eye, nose, or...

514476, 514491, 514974, A61K 3127

Patent

active

045812241

ABSTRACT:
Dithiocarbamic compounds, administered about 0.5 to about 6 hours after Pt compounds, have been found to counter the toxicity of the platinum in multi-cellular organisms (e.g. mammals). For example, neoplastic growths in mammals can be treated with cis-diamine or cis-diamine Pt(II) complexes with greatly lessened risk of nephrotoxicity, bone marrow toxicity, or damage to the digestive system of the mammal, provided the dithiocarbamic compound is timely (and preferably parenterally) administered. Particularly effective dithiocarbamic compounds are monomeric (e.g. ##STR1## where M is a pharmaceutically acceptable cation and R.sup.1 and R.sup.2 are lower aliphatic (or cycloaliphatic or heterocycloaliphatic groups) or, less preferably, dimeric, e.g. ##STR2## wherein R.sup.1 and R.sup.2 are as defined previously, and R.sup.3 and R.sup.4 are defined in the same manner as R.sup.1 and R.sup.2. These dithiocarbamic compounds do not significantly reduce the desired effect of the Pt(II) compounds (particularly when the dithiocarbamic compound is intravenously admininstered), despite their effectiveness in reducing harmful side effects.

REFERENCES:
patent: 4053587 (1977-10-01), Davidson et al.
patent: 4137248 (1979-01-01), Gale et al.
Lin et al., C.A. vol. 91 (1979) 91:117,166d.
Borch et al.; Proc. Natl. Acad. Sci. (USA), vol. 76, No. 12, pp. 6611-6614 (1979).
Thorn et al., The Dithiocarbomates and Related Compounds, Elsevier, Amsterdam, 1962, Chapters 3 and 8.
Chem. Abs. 91:117166d (1979).
Einhorn et al., NEJM 300: 289-291 (1979).
Borch et al., Proc. Natl. Acad. Sci. USA, and 77: 5441 (1980).
Cancer Treatment Reports 62: 1431,1433-1444, 1475-1483, 1493-1502, 1527-1531 (1979).
Borch et al., Analyt. Letters, 12(B8): 917 (1979).
Sunderman, Ann. Clin., Res. 3:182 (1971).
National Formulary XIV, 14th Ed., pp. 237-238 (1979).
New Ethicals Catalogue, Dec. 1978, p. A8.
Physician' Desk Reference, 1965 ff., "Antabuse".
Research and Invention, Winter 1972 and 1977-1978.
List of references cited in Great Britain (attached) and copies thereof.
Slater et al., J. Clin. Hematol. Oncol. 7:534-546 (1977).
Connors, Advances in Antimicrobial and Antineoplastic Chems. Therapy, University Park Press, Baltimore 1972, vol. 2, pp. 237-238.
Filipski et al., Science, 204:181-183 (1979).
Cafruny, Pharmacological Rev. 20:89.116 (1968).
Burchenol et al., Viochimie 60:961-965 (1978).
Cafruny et al., J. Pharmacol Exp. Ther., 117:101 (1956).
Dieke et al., J. Pharmacol. Exp. Ther. 83:195-202 (1948).
AACR Abstracts (Higby et al) 16:523A (1975).
Sunderman, Ann. Clin. Lab. Sci., 9:1-10 (1979).
Hayes et al., Cancer 39:1372-1381 (1977).
Cvitkovic et al., Cancer 39:1357-1361 (1977).
Astwood, J. Pharmacol.Exp.Ther., 78:79-91 (1943).

Affiliated with

Also associated with

Rating

Inhibition of undesired effect of platinum compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibition of undesired effect of platinum compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of undesired effect of platinum compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2065195